在牛皮安全网诊所获得生物疗法的公平准入:一项回顾性队列研究
Sammya Mufarrej1, Franco Rongioletti2, Paolo Romanelli1
1Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, United States.
Clinics in dermatology
|December 24, 2025
概括
对于没有保险的患者来说,获得牛皮的生物疗法是一项挑战. 安全网模型改善了接入,但并没有消除生物治疗中的种族和保险差异.
科学领域:
- 皮肤病学 皮肤病学
- 医疗保健服务研究 医疗服务研究
- 健康 公平 卫生 公平
背景情况:
- 对于没有保险或保险不足的人来说,获得牛皮的生物疗法往往是有限的.
- 现有的安全网系统和制造商援助计划可能无法完全解决这些进入障碍.
研究的目的:
- 评估联合医院财政援助和制造商支持模式在促进牛皮患者启动生物治疗的有效性.
- 在这个安全网模型中识别生物获取障碍.
主要方法:
- 在杰克逊纪念医院的牛皮生物学诊所治疗的187名牛皮患者的回顾性队列研究 (2020年1月 - 2025年5月).
- 评估患者的资格,生物处方率和启动障碍.
- 分析保险来源,包括政府计划,医院援助和不足保险的计划.
主要成果:
- 67.4%的患者被处方为生物药物,其中阿达利马布和塞库金马布是最常见的.
- 启动障碍影响了15.5%的患者,主要是由于保险拒绝或失败.
- 几乎所有患者都没有经历过共同支付,而那些使用医院援助的人免费获得了生物药物.
结论:
- 综合安全网模型成功使大多数牛皮患者能够获得生物治疗.
- 持续存在的种族和保险相关差异凸显了系统性和政策层面干预的必要性.
- 为了实现对牛皮生物制剂的公平获取,需要解决超越个人患者援助的更广泛的结构性问题.
相关概念视频
Bioequivalence studies: Biowaivers
203
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
203
Drug Products: Biologics, Biosimilars and Interchangeables
214
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
214
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
376
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
376
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
437
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
437
Bioavailability Study Design: Healthy Subjects Versus Patients
130
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
130
Bioequivalence of Drugs: Drugs with Multiple Indications
138
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
138


